View Older Stories View More Recent Stories
-
Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
Amgen plans $650 million manufacturing expansion, creating 750 jobs
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
William Blair on Sanofi (SNY): 'We believe it will be important to see the efficacy broken out by prior advanced therapy'
-
Regeneron (REGN) See Strength Following Opening Bell Weakness, Now up Over 2pct
-
Regeneron (REGN) Shares Decline on the Open
-
Raymond James Comments on REGN and AMGN Earlier
-
Zai Lab pauses regulatory filing for bemarituzumab after trial results
-
AMGEN plans $600 million science center at California headquarters
-
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
-
Amgen (AMGN) PT Raised to $342 at Piper Sandler
-
FDA expands AMGEN's Repatha approval for cardiovascular risk reduction
-
Amgen (AMGN) PT Lowered to $335 at Bernstein Amid MariTide Risk
-
U.S. Government's Announcement On Pharma Sector Probe And Tariffs Unlikely For A Few Weeks, Sources Say - Reuters
-
Cantor Fitzgerald Reiterates Neutral Rating on Amgen (AMGN)
-
Amgen (AMGN) PT Raised to $330 at RBC Capital on 'Solid Beat And Raise'
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
BMO Capital: 'Strong Print Sets Amgen (AMGN) Shares Back on Track'
-
Amgen (AMGN) Tops Q2 EPS by 76c, Offers Guidance
-
Amgen (AMGN) call put ratio 2.3 calls to 1 put into quarter results
-
Amgen (AMGN) Declares $2.38 Quarterly Dividend; 3.2% Yield
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
Amgen (AMGN) PT Raised to $261 at BofA Securities
-
Amgen (AMGN) PT Raised to $305 at Citi
-
Amgen (AMGN) PT Raised to $326 at UBS
-
U.S. large biotech stocks Q2 earnings preview
-
Amgen (AMGN) PT Lowered to $335 at BMO Capital
-
Piper Sandler on Amgen (AMGN): 'Another Clinical Win For The Oncology Franchise'
-
William Blair Reiterates Outperform Rating on Amgen (AMGN)
-
Amgen (AMGN) Announces Positive Topline Phase 3 Results For Bemarituzumab In Fibroblast Growth Factor Receptor 2B (Fgfr2B) Positive First-line Gastric Cancer
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
BMO Capital Reiterates Outperform Rating on Amgen (AMGN)
-
Truist Securities Reiterates Hold Rating on Amgen (AMGN)
-
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
-
Cantor Fitzgerald Reiterates Neutral Rating on Amgen (AMGN)
-
Amgen (AMGN) reports full results from Part 1 of the Phase 2 study of MariTide
-
Jefferies Downgrades Vigil Neuroscience Inc (VIGL) to Hold
-
Amgen (AMGN) PT Trimmed to $328 at Piper Sandler
-
Regeneron (REGN) Prevails over Amgen (AMGN) in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
-
Popular stocks volume: AMGN GILD JNJ LLY MRK PFE SNY AZN GSK NVS BMY NVO CVS CI UNH CAH MCK COR W RH
-
Erste Group Downgrades Amgen (AMGN) to Hold
-
Amgen (AMGN) option IV flat
-
Cantor Fitzgerald Reiterates Neutral Rating on Amgen (AMGN)
-
Stocks expected to have increasing option volume: SYK AMGN FIVN CART TWLO BMRN PCTY JNPR WEN CI CYTK TWLO
-
Amgen (AMGN) Tops Q1 EPS by 61c; offers guidance
-
Amgen (AMGN) call put ratio 3.3 calls to 1 put into quarter results
-
Amgen (AMGN) confirms $900M Ohio manufacturing expansion
-
Amgen (AMGN) Announces $900 Million Expansion Of Ohio Drugmaking Plant - Bloomberg
